查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496009

全球細胞採集市場 - 2024 年至 2029 年預測

Global Cell Harvesting Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

細胞採集市場預計將從2022年的20.88億美元成長到2029年的210.9億美元，複合年成長率為39.15%。

預計在預測期內推動市場成長的主要原因是患者中癌症和殘疾病例數量的增加。根據世界衛生組織（WHO）資料，2020年全球新診斷主流癌症病例超過1,010萬例。同年該疾病導致超過 5,019,000 人死亡。細胞採集和細胞治療是預計將推動市場成長的主要癌症治療方法。

此外，醫療保健和健康研發支出的增加導致了早期檢測和更好治療的產品創新，預計這將擴大市場範圍。此外，預計意識的提高將支持預測期內的市場成長。癌症是一種全球性疾病，但生存機率因地區的醫療基礎設施和意識而異。

根據世界衛生組織的資料，在已開發國家，診斷出癌症的患者的存活率約為90%。印度的存活率低至 66%，南非的存活率較低，為 40%。在已開發國家，已證實早期發現和治療可以提高患者的存活率。然而，在開發中國家，適當的治療對存活率有重大影響。

細胞移植和細胞療法是用於治癒患有特定癌症類型和細胞疾病的患者的典型治療方法。根據蓋爾研究所的資料，幹細胞療法對 45% 的治療患者有效。技術進步預計將提高功效並為細胞採集市場帶來顯著成長。由於該地區醫療旅遊業的興起，預計亞太地區細胞採集市場將呈指數級成長。

市場促進因素：

  • 癌症患者數量的增加和健康意識的增加預計將推動市場成長。

推動細胞採集市場成長的主要原因是癌症患者數量的增加。根據世界衛生組織關於乳癌的報告，2020年全球將有230萬名女性被診斷出罹患乳癌，全球將有780萬人受到乳癌的影響。同年，685,000 名女性死於乳癌，使其成為女性癌症死亡的主要原因。

此外，新增肺癌確診病例221萬例，新增大腸直腸癌確診193萬例。這兩種類型是癌症死亡的主要原因，2020 年分別奪走 180 萬人和 935,000 人的生命。皮膚癌新增病例也達 120 萬人。對病例數量不斷增加以及生活方式日益複雜的嚴重擔憂導致對早期診斷的投資增加。已經證實，早期診斷可以提高患者的存活率並降低癌症死亡率。

此外，細胞療法是治療乳癌、大腸癌和皮膚癌的有效治療方法。過去 30 年來，高所得國家的大量投資已將癌症死亡率降低了 40%。此外，世界衛生組織估計，在 2020 年至 2040 年間，每年將癌症死亡率降低 2-4%，可避免 250 萬人死於乳癌。

在 GBCI 的領導下，該組織旨在透過更好的醫療技術和基礎設施來提高意識並鼓勵早期檢測實踐。此外，該組織的目標是建立集中的診斷和治療服務，以取得更好的結果。預計投資的增加將推動市場對細胞採集技術的需求。

市場限制因素：

  • 細胞治療的高成本可能會阻礙細胞採集產業的市場規模。

細胞採集市場面臨的主要限制之一是細胞治療的成本極高。細胞採集裝置用於細胞治療，從捐贈者或患者身上收集細胞。然而，細胞療法既昂貴又耗時。高昂的費用和時間浪費使患者不願意選擇這種治療方法。此外，化療和手術等更便宜的替代療法的可用性也阻礙了市場的成長。

主要進展

  • 2022 年 9 月 - Thermo Fisher Scientific 推出專為大規模細胞培養物收集而設計的 DynaSpin 拋棄式離心系統。該系統透過減少所需的深度過濾筒的數量來簡化收穫，從而與傳統收穫系統相比，獲得相似或更高的產品產量。 DynaSpin 系統還提高了生技藥品製造的營運效率、成本節約和永續實踐。消除了 70% 的廢棄物，所需材料減少了 6 倍。該系統還融合了一次性產品的優點，包括可擴展性、快速轉換、減少停機時間和降低污染風險。 DynaSpin 目前可在全球購買。
  • 2022 年 6 月—雪梨科技大學和 Regeneus 的研究人員開發了一種 3D 列印微流體幹細胞採集裝置，為處理幹細胞提供了一種經濟有效且可擴展的方法。研究團隊開發了一種3D列印的微流體幹細胞採集裝置，能夠從反應器中高品質、廣泛地生產幹細胞。這項技術整合了D列印和微流體技術，有望使幹細胞療法以更低的成本得到更廣泛的應用。該系統目前處於原型階段，可處理間質幹細胞，它可以分裂並分化成多種組織細胞。
  • 2022 年 6 月 - 根據內分泌學會年會 ENDO2022 上進行的一項臨床研究，建議將一種名為 PEC-Direct 的幹細胞治療方法用於替代胰腺，用於 1 型糖尿病高風險患者。在這項研究中，使用這種新治療方法的幾名患者的 C胜肽（一種與胰島素一起在胰腺中產生的物質）出現了臨床相關的增加。 PEC-Direct 裝置提供長期、穩定的胰島素來源來調節血糖濃度，適用於容易出現急性併發症的高風險 1 型糖尿病患者。
  • 2022 年 6 月 - Meso Numismatics, Inc. 與 Ramzan Ali 幹細胞中心簽署了一項為期五年的協議，以擴大其在全球第五大人口醫療保健市場巴基斯坦的服務。此次合作旨在透過建立細胞治療卓越中心來擴大全球幹細胞集團的品牌，以滿足亞洲和中東市場的需求。該合作夥伴關係將建立一個醫療技術中心，涵蓋五個城市的醫療培訓，舉辦年度會議以提高人們對細胞療法益處的認知，並推出 GSCG 的細胞產品，例如 CELLGENIC胞外體系列。

主要市場區隔：

依收藏類型

  • 手動細胞採集
  • 自動細胞採集

依幹細胞類型

  • 臍帶幹細胞
  • 成體幹細胞
  • 胎兒幹細胞
  • 胚胎幹細胞
  • 其他

按用途

  • 癌症
  • 血液疾病
  • 遺傳疾病
  • 其他

按最終用戶

  • 生物技術和生物製藥公司
  • 醫院
  • 研究中心

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 其他
  • 中東/非洲中東/非洲
  • UAE
  • 沙烏地阿拉伯
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球細胞收穫市場：依收穫類型

  • 介紹
  • 手動細胞採集
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 自動細胞採集
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球細胞採集市場：依幹細胞類型

  • 介紹
  • 臍帶幹細胞
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 成體幹細胞
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 胎兒幹細胞
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 胚胎幹細胞
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章 全球細胞採集市場：依應用分類

  • 介紹
  • 癌症
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 血液疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 遺傳疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球細胞收穫市場：依最終用戶分類

  • 介紹
  • 生物技術和生物製藥公司
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 醫院
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 研究中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第9章全球細胞收穫市場：按地區

  • 介紹
  • 北美洲
    • 按收穫類型
    • 依幹細胞類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按收穫類型
    • 依幹細胞類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按收穫類型
    • 依幹細胞類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按收穫類型
    • 依幹細胞類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按收穫類型
    • 依幹細胞類型
    • 按用途
    • 按最終用戶
    • 按國家/地區

第10章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • PerkinElmer Inc.
  • Tomtec
  • CTIBiotech
  • RegenMed Systems Inc.
  • Aspire Medical Innovation
  • Sartorius AG
  • Terumo Corporation
簡介目錄
Product Code: KSI061611917

The global cell harvesting market is projected to witness a compound annual growth rate of 39.15% to grow to US$21.090 billion by 2029, from US$2.088 billion in 2022.

The prime reason that is expected to drive the market growth during the forecasted period is the rising cases of cancers and disorders among patients. Data from the World Health Organization (WHO) shows that in 2020, more than 10.1 million new cases of mainstream cancer were diagnosed globally. The disease led to more than 5.019 million deaths in the year. Cell harvesting and cell therapy are leading cancer treatments that are expected to drive market growth.

Moreover, increasing expenditure in healthcare and health research and development has led to the innovation of products for early detection and superior treatment, which is expected to increase the market scope. Furthermore, increasing awareness is projected to support the market growth during the forecasted period. While cancer is a global disease, different regions have different survival chances based on the healthcare infrastructure and awareness.

Data from WHO shows that survival chances for a patient diagnosed with cancer range around 90% in developed nations. In India, the survival chance is as low as 66% while in South Africa, it is even lower to 40%. It has been observed that early detection and treatment in developed nations successfully increase the survival chances of patients. However, in developing nations, adequate treatment significantly affects the survival chances.

Cell transplant and cell therapy are leading treatments that are used to cure a patient with certain cancer types and cell disorders. Data from The Guyer Institute shows that stem cell therapy is effective in 45% of the treated patients. Advancement in technology is expected to increase the effectiveness and hence provide substantial growth for the cell harvesting market. The Asia Pacific cell harvesting market is projected to grow at an exponential rate owing to increasing medical tourism in the region.

Market Drivers:

  • Increasing cancer cases and health consciousness are anticipated to surge the market growth.

The prime reason driving the market growth of the cell harvesting market is the rising cases of cancer. WHO report on breast cancer shows that in 2020, 2.3 million women globally were diagnosed with breast cancer, adding to a total active case of 7.8 million worldwide. 685,000 women died of breast cancer in the year, making it one of the leading cancer-causing death diseases among women.

Additionally, 2.21 million new cases of lung cancer were diagnosed while 1.93 million new cases of colon and rectum cancer were discovered. These two types were the leading cause of cancer deaths, taking 1.80 million lives and 0.935 million lives, respectively, in 2020. The skin was another leading cancer with 1.20 million new cases. Complex lifestyles along with increasing complexities have raised serious concerns about rising cases, leading to higher investment in early diagnosis. It has been observed that early diagnosis increases the survival chance of the patient and hence reduces cancer mortality.

Furthermore, cell therapy is an effective treatment to cure breast, colon rectum, and skin cancer. Substantial investment by higher-income countries has led to the successful reduction of cancer mortality by 40% in the past 3 decades. Furthermore, WHO estimates that a reduction of cancer mortality by 2-4% per year between 2020 to 2040 will avoid 2.5 million potential breast cancer deaths.

Under GBCI, the organization aims to increase awareness and encourage early detection practice through better healthcare technology and infrastructure. Furthermore, the organization aims to establish centralized services for diagnosis and treatment for better results. The rising investment is expected to drive the market demand for cell harvesting technology.

Market Restraint:

  • The significant cost of cell therapy could hinder the market size of the cell harvesting industry.

One of the prime constraints faced by the cell harvesting market is the significantly high cost of cell therapy treatment. Cell harvesting devices are used in cell therapy treatment for the extraction of cells from donors or patients. However, cell therapy treatment is an expensive procedure and takes time. High cost and time utilization discourage patients to opt for this treatment. Furthermore, the availability of less expensive substitutes such as chemotherapy and surgery, in cancer hinders the market growth.

Key Developments:

  • September 2022- Thermo Fisher Scientific introduced the DynaSpin Single-Use Centrifuge system, designed for large-scale cell culture harvesting. The system streamlines harvesting by reducing the number of depth filtration cartridges needed, resulting in equivalent or improved product yield compared to traditional harvest systems. The DynaSpin system also offers operational efficiency, cost savings, and sustainable practices in biologics production. It eliminates 70% of waste and offers a six-fold reduction in material requirements. The system also incorporates advantages of single-use products, including scalability, rapid change over, reduced downtime, and lower risk of contamination. The DynaSpin is now available globally for purchase.
  • June 2022- Researchers from the University of Technology Sydney and Regeneus developed a 3D-printed microfluidic stem cell harvester, offering a cost-effective, scalable method for processing stem cells. They have developed a 3D-printed microfluidic stem cell harvester, allowing for high-quality, wide-scale production of stem cells from bioreactors. The technology, which integrates 3D printing and microfluidics, expected to make stem cell therapies more widely available at a lower cost. The system, currently in the prototype stage, processes mesenchymal stem cells, which can divide and differentiate into multiple tissue cells. The researchers are working closely with biotechnology companies to commercialize the innovative technology.
  • June 2022- A clinical study at ENDO 2022, the Endocrine Society's annual meeting suggests that stem cell-based therapy called PEC-Direct, designed to replace the pancreas, could potentially provide blood sugar control in patients with high-risk type 1 diabetes. The study found that multiple patients using the new treatment had clinically relevant increases in C-peptide, a substance made in the pancreas along with insulin. The PEC-Direct device provides a long-term, stable source of insulin to regulate glucose levels, and is intended for patients with high-risk type 1 diabetes who may be vulnerable to acute complications.
  • June 2022- Meso Numismatics, Inc. signed a 5-year contract with Ramzan Ali Stem Cell Center to expand its services in Pakistan, the world's 5th most populous healthcare market. The partnership aims to expand the Global Stem Cell Group brand by creating excellence centers in cell therapy to meet demand in Asian and Middle Eastern markets. The alliance established a medical technology center, cover medical training in five cities, hold an annual congress to raise awareness of cellular medicine benefits, and launch GSCG's cellular products, such as the CELLGENIC line of exosomes.

Key Market Segments:

By Harvesting Type

  • Manual Cell Harvesting
  • Automated Cell Harvesting

By Stem Cell Type

  • Umbilical Cord Stem Cells
  • Adult Stem Cells
  • Fetal Stem Cells
  • Embryonic Stem Cells
  • Others

By Application

  • Cancer
  • Blood Disorder
  • Genetic Disorder
  • Others

By End Users

  • Biotechnology & Biopharmaceutical Companies
  • Hospitals
  • Research Centers

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL CELL HARVESTING MARKET, BY HARVESTING TYPE

  • 5.1. Introduction
  • 5.2. Manual Cell Harvesting
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Automated Cell Harvesting
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL CELL HARVESTING MARKET, BY STEM CELL TYPE

  • 6.1. Introduction
  • 6.2. Umbilical Cord Stem Cells
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Adult Stem Cells
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Fetal Stem Cells
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Embryonic Stem Cells
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL CELL HARVESTING MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Cancer
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Blood Disorder
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Genetic Disorder
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL CELL HARVESTING MARKET, BY END USERS

  • 8.1. Introduction
  • 8.2. Biotechnology & Biopharmaceutical Companies
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Hospitals
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Research Centers
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness

9. GLOBAL CELL HARVESTING MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Harvesting Type
    • 9.2.2. By Stem Cell Type
    • 9.2.3. By Application
    • 9.2.4. By End Users
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Harvesting Type
    • 9.3.2. By Stem Cell Type
    • 9.3.3. By Application
    • 9.3.4. By End Users
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Harvesting Type
    • 9.4.2. By Stem Cell Type
    • 9.4.3. By Application
    • 9.4.4. By End Users
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. Germany
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. Spain
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. France
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Others
        • 9.4.5.5.1. Market Opportunities and Trends
        • 9.4.5.5.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Harvesting Type
    • 9.5.2. By Stem Cell Type
    • 9.5.3. By Application
    • 9.5.4. By End Users
    • 9.5.5. By Country
      • 9.5.5.1. UAE
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. Saudi Arabia
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Harvesting Type
    • 9.6.2. By Stem Cell Type
    • 9.6.3. By Application
    • 9.6.4. By End Users
    • 9.6.5. By Country
      • 9.6.5.1. Japan
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. China
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. PerkinElmer Inc.
  • 11.2. Tomtec
  • 11.3. CTIBiotech
  • 11.4. RegenMed Systems Inc.
  • 11.5. Aspire Medical Innovation
  • 11.6. Sartorius AG
  • 11.7. Terumo Corporation